Meg Hooton

R&D

Meg Hooton, President of IQVIA Biotech, leads the organisation, providing clinical development solutions for biotech and emerging biopharma clients.

News

Neuraxpharm and Minoryx' Nezglyal has become the first approved drug therapy in the EU for rare neurodegenerative disease cALD.

Digital

A new webinar from Konovo will address some of the critical topics impacting today’s healthcare market research industry.